Cue Biopharma (CUE) Intangibles (2017 - 2018)
Cue Biopharma's (CUE) quarterly Intangibles came in at $175000.0 in Q3 2018, little changed quarter-over-quarter from $175000.0 in Q2 2018.
Analysis
Cue Biopharma (CUE) Intangibles (2017 - 2018) Analysis & Trends
Cue Biopharma has disclosed Intangibles across 2 years of filings, most recently posting $175000.0 for Q3 2018.
- In Q3 2018, Intangibles changed N/A year-over-year to $175000.0; the TTM figure through Sep 2018 stood at $175000.0 (changed N/A YoY), while the FY2017 annual figure was $175000.0, changed N/A from the prior year.
- Intangibles came in at $175000.0 for Q3 2018 at Cue Biopharma, roughly flat from $175000.0 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $175000.0 in Q4 2017 to a low of $175000.0 in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 20.49 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 14.03 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 412.80 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.31 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 266.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 13.52 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Cue Biopharma | 179.95 Mn | 162.53 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2018 | 175,000.00 |
| Jun 30, 2018 | 175,000.00 |
| Mar 31, 2018 | 175,000.00 |
| Dec 31, 2017 | 175,000.00 |